Plasmodium vivax is classified into two serotypes, VK210 [the dominant form- GDRA(D/A)GQPA repeats] and VK247 [the variant form-ANGA(G/D)(N/D)QPG repeats], based on sequence variation of the repeat region of the circumsporozoite (CS) protein gene.
This review summarises the antimalarials developed and registered thus far, as well as describing some of the new small molecule therapy approaches being developed as a contribution towards the malaria eradication agenda.
Plasmepsins, a family of aspartic proteases of Plasmodium species, are known to participate in a wide variety of cellular processes essential for parasite survival.
Based on the limited number of samples, prevalence of CQ and SP resistance at molecular levels in the population in the study area were determined as high in P. falciparum and low in P. vivax.
We investigated the therapeutic efficacy of HCQ and the pvmdr1 gene polymorphisms in P. vivax. From June to September 2006, 102 soldiers with vivax malaria near the demilitarized zone in Gyeonggi-do, ROK, were enrolled in the study.
The identification and partial characterization of the first P. vivax rhoptry neck protein are described in the present study.
This study, the first preclinical evaluation of adenovirus-vectored malaria OSPs, implicates a potential inclusion of malaria transmission-blocking vaccine antigens in viral vector systems.
Considering that antigens included in a subunit malaria vaccine should be both accessible to the immune system and lack genetic diversity or have very limited polymorphism, we have analyzed the genetic diversity of three msp genes (msp-7A, msp-7K and msp-10) in different geographical regions of Colombia. The results showed that these genes follow the neutral model of evolution and also display low genetic diversity.
Overall, our results illustrate that PNG malaria-endemic regions harbor a complex mixture of P. vivax strains, and emphasize the importance of malaria control strategies that would be effective against a highly diverse parasite population.
Plasmodium species ex vivo sensitivity assay protocols differ in the requirement for leukocyte removal before culturing.